Perspective Therapeutics Inc (CATX) financials
Perspective Therapeutics revenue and earnings by year
Perspective Therapeutics's revenue was $884,000 in the fiscal year to December 31, 2025, down 39.2% from the year before. Net income was -$103 million, -11665.3% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 1 | 1 | 1 |
| Revenue growth | -39.2% | 1.4% | — |
| Operating income | -114 | -91 | -41 |
| Operating margin | -12846.6% | -6250.8% | -2855.0% |
| Net income | -103 | -79 | -47 |
| Net margin | -11665.3% | -5452.5% | -3243.2% |
| Diluted EPS | -$1.40 | -$1.23 | -$1.74 |
| Free cash flow | -95 | -72 | -38 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CATX in Markets.
See also: CATX returns
No forecast, no recommendation. This page describes Perspective Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.